glp 1 cardiovascular risk reduction Glucagon-like peptide receptor agonists: benefits and mechanisms of action The Many Cardiovascular Benefits of

27 A timeline of different trials regarding GLP-1 RAs is presented in Figure 1

See recent WSJ article here Enthusiasts (biohackers?) and some longevity-focused clinicians believe that microdosing these drugs offers benefits beyond weight loss, such as improved metabolic health, glycemic control, reduced systemic inflammation, and potentially even a lower risk of age-related diseases

The widespread use of these drugs for weight loss has sparked debates as to the medicalisation of obesity and the ethics of using pharmaceuticals for body modification (Arillotta et al., 2023)

7 , e007301 (2018)

Extremely low prices compared to market averages may indicate compromised product quality or inadequate safety measures

van Es A et al